A natural breast for cancer survivors: resorbable implant supporting tissue regenerationbroad
regenera · Horizon Europe grant · 2023-03-01–2025-02-28
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
Of the 3 million women undergoing breast cancer resection every year, only a few opt for breast reconstruction due to pain, concerns about follow-up procedures and the lack of options. For lumpectomy patients traditional implants cannot be used, with only ~20-30% of lumpectomies being reconstructed. Autologous tissue transfer requires multiple painful interventions to reconstruct large volumes and obtain satisfactory results. Furthermore, both implants and autologous solutions require multiple follow-up surgeries, increasing costs and pain for the patients. REGENERA will be a unique solution for lumpectomy patients: a resorbable implant designed to restore a natural breast through tissue self-regeneration. It is a cell-free porous scaffold made of resorbable biocompatible poly(urethane-ester-ether) with a biomimetic architecture. It is designed to avoid follow-up surgeries and eliminate the risks associated with silicone and saline implants (rupture, leakage, ALCL) and fat grafting.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| TENSIVE SRL | IT | coordinator | €2,498,600 | Yes |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.